RGFP 966

Key Product Details

Product Description

RGFP 966 is a potent and selective HDAC3 inhibitor (IC₅₀ = 80 nM); exhibits no effect on other HDAC (up to 15 μM). RGFP 966 reduces the frequency of striatal CAG repeat expansions in mouse models of Huntington's disease and reduces mHTT accumulation. RGFP 966 blocks the formation of reactive astrocytes and, in vivo, it is neuroprotective and enhances long-term object-location memory.

Product Specifications for RGFP 966

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for RGFP 966

The following data is based on the product molecular weight 362.40.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.76 mL	13.80 mL	27.59 mL
5 mM	0.55 mL	2.76 mL	5.52 mL
10 mM	0.28 mL	1.38 mL	2.76 mL
50 mM	0.06 mL	0.28 mL	0.55 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 4 publications citing the usage of this product.

• Suelvez A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice. Sci.Rep. 2017 PMID: 28729730
• Clayton A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity. Nat.Neurosci. 2024 PMID: 38378993
• Malvaez HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc.Natl.Acad.Sci.USA. 2013 PMID: 23297220

Product Documents for RGFP 966